Does ibrutinib/Eco need to be taken for a long time? What are the recommendations?

Ibrutinib/Ibrutinib (Ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that targets B cells. It is mainly used for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and some low-grade malignant B-cell lymphomas. BTK plays a central role in the B cell receptor signaling pathway and plays a key role in the development of B cell malignant diseases by regulating B cell proliferation, survival and migration. Ibrutinib irreversibly inhibits BTK activity and blocks abnormal signaling pathways, thereby inhibiting tumor cell proliferation, reducing tumor burden, and delaying disease progression.

In clinical practice, most patients require long-term oral ibrutinib to maintain disease control. The main goals of long-term medication are to delay relapse, maintain remission, and improve quality of life. Patients should undergo regular hematology tests, heart function assessment, and liver and kidney function monitoring during medication to detect potential risks in a timely manner. Some common side effects that may occur with long-term use include mild bleeding, increased risk of infection, abnormal heart rhythm, or mild fatigue. For patients who are elderly or have underlying cardiovascular disease, doctors may adjust the dose or interval based on blood pressure, heart rate, and blood indicators.

In terms of medication management, it is recommended that patients swallow the tablets whole and do not chew or crush the medication. They can also take it on an empty stomach or with food to improve compliance. If you miss a dose, you should continue taking it as originally planned. It is not recommended to take it all at once. During initial use, doctors usually closely monitor blood routine and infection indicators to reduce the risk of side effects. Through scientific management and regular follow-up, ibrutinib can provide patients with a long-term and stable disease control plan and is the core drug for maintenance treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Reference materials:https://www.imbruvica.com/